Similar articles

• Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.

  Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Arellano FM, et al. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):861-72. doi: 10.1002/pds.1343. Pharmacoepidemiol Drug Saf. 2006. PMID: 17086563
• Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations.

  Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Arana A, Rothman KJ. Arellano FM, et al. Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):1037. doi: 10.1002/pds.1636. Pharmacoepidemiol Drug Saf. 2008. PMID: 18816876 No abstract available.
• Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

  Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S. Moride Y, et al. Arthritis Res Ther. 2005;7(2):R333-42. doi: 10.1186/ar1488. Epub 2005 Jan 17. Arthritis Res Ther. 2005. PMID: 15743481 Free PMC article.
• The use of NSAIDs in rheumatic disorders 2005: a global perspective.

  Kean WF, Buchanan WW. Kean WF, et al. Inflammopharmacology. 2005;13(4):343-70. doi: 10.1163/156856005774415565. Inflammopharmacology. 2005. PMID: 16354389 Review.
• Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.

  Bruno A, Tacconelli S, Patrignani P. Bruno A, et al. Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):56-63. doi: 10.1111/bcpt.12117. Epub 2013 Sep 3. Basic Clin Pharmacol Toxicol. 2014. PMID: 23953622 Review.